Free Trial
NASDAQ:SLGL

Sol-Gel Technologies (SLGL) Stock Price, News & Analysis

$0.64
+0.04 (+6.67%)
(As of 10:30 AM ET)
Today's Range
$0.62
$0.66
50-Day Range
$0.37
$0.96
52-Week Range
$0.33
$2.93
Volume
253,286 shs
Average Volume
157,034 shs
Market Capitalization
$17.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Sol-Gel Technologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
733.3% Upside
$5.00 Price Target
Short Interest
Healthy
4.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Sol-Gel Technologies in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

Medical Sector

374th out of 924 stocks

Pharmaceutical Preparations Industry

166th out of 426 stocks

SLGL stock logo

About Sol-Gel Technologies Stock (NASDAQ:SLGL)

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

SLGL Stock Price History

SLGL Stock News Headlines

$5k to $1.3m in just 3 trades
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Sol-Gel Technologies (NASDAQ:SLGL) Announces Quarterly Earnings Results
$5k to $1.3m in just 3 trades
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Sol-Gel Technologies Ltd SLGL
Sol-Gel Technologies Ltd.
See More Headlines
Receive SLGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sol-Gel Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/16/2024
Today
8/22/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLGL
Employees
50
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+675.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-27,240,000.00
Net Margins
-227.40%
Pretax Margin
-1,329.13%

Debt

Sales & Book Value

Annual Sales
$1.55 million
Book Value
$1.67 per share

Miscellaneous

Free Float
9,330,000
Market Cap
$17.97 million
Optionable
Optionable
Beta
1.54

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Alon Seri-Levy (Age 63)
    Co-Founder, CEO & Director
    Comp: $411k
  • Mr. Gilad Mamlok (Age 56)
    Chief Financial Officer
    Comp: $367k
  • Dr. Itzik Yosef (Age 48)
    Chief Operating Officer
    Comp: $236k
  • Mr. Moshe Arkin (Age 71)
    Executive Chairman of the Board
  • Prof. David Avnir
    Co-Founder
  • Ms. Tamar Fishman Jutkowitz (Age 48)
    VP & General Counsel
  • Dr. Karine Neimann (Age 53)
    VP of Projects & Planning and Chief Chemist

SLGL Stock Analysis - Frequently Asked Questions

How have SLGL shares performed this year?

Sol-Gel Technologies' stock was trading at $1.1050 on January 1st, 2024. Since then, SLGL shares have decreased by 45.7% and is now trading at $0.60.
View the best growth stocks for 2024 here
.

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) released its quarterly earnings results on Friday, August, 16th. The company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.27. The company earned $5.43 million during the quarter, compared to the consensus estimate of $1.06 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 39.11% and a negative net margin of 227.40%.

When did Sol-Gel Technologies IPO?

Sol-Gel Technologies (SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

Who are Sol-Gel Technologies' major shareholders?

Sol-Gel Technologies' top institutional shareholders include Armistice Capital LLC (7.29%).

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Sol-Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sol-Gel Technologies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR) and Teva Pharmaceutical Industries (TEVA).

This page (NASDAQ:SLGL) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners